Dancann Pharma

Danmark har tagit ett viktigt steg mot att integrera cannabinoidbaserade läkemedel i sitt nationella sjukvårdssystem genom att anta lagförslag L135, med 101 röster för och 10 emot. Jeppe Krog Rasmussen, VD för DanCann Pharma A/S, ser detta som en bekräftelse på den viktiga roll medicinsk cannabis kan ha i patientvården. Den nya lagen ger klarhet i regleringen, säkrar fortsatt tillgång för patienter under medicinsk övervakning och ger företag som DanCann Pharma en stabil grund för investering och utveckling. För DanCann Pharma innebär detta en permanent rättslig grund för kommersiella aktiviteter, förstärkning av Danmarks position i Skandinavien inom cannabinoidterapier, och möjliggör långsiktig affärsplanering och internationella partnerskap. Företaget ser fram emot att samarbeta med myndigheter och branschpartners under den nya lagstiftningen. DanCann Pharma är ett danskt biopharmaceuticalföretag grundat 2018 och noterat på Spotlight Stock Market i Köpenhamn/Stockholm.

The financial calendar for DanCann Pharma A/S in 2025 includes the release of the Annual Report 2024 on April 4, the Annual General Meeting on April 24, the Q1 2025 Report on May 23, the Q2 2025 Report on August 25, and the Q3 2025 Report on October 27. DanCann Pharma A/S is a Danish biopharmaceutical company specializing in cannabinoids and is listed on the Spotlight Stock Market. The company provides a forward-looking statement, indicating that predictions about future events are subject to risks and uncertainties that could cause actual outcomes to differ. The company advises caution in relying on these statements and notes they are not obligated to update them unless legally required. For more information, visit their website or contact CEO Jeppe Krog Rasmussen.

On 24 April 2025, the annual general meeting of the Company was held in Ansager, Denmark. The agenda included reports on the past year's activities, adoption of the 2024 annual report, and decisions on financial losses. The re-election of board members and the auditor was confirmed. The meeting approved the remuneration for the board for 2025 and discussed changes to share capital, including a reverse share split and the cancellation of treasury shares. The board was authorized to increase share capital and issue warrants, both with and without pre-emption rights, until 2030. No shareholder proposals were received, and no other business was discussed. The meeting was chaired by attorney Michael Kristensen.

The Board of Directors of DanCann Pharma A/S has scheduled the annual general meeting for April 24, 2025, at their address in Ansager, Denmark. The agenda includes the chairman’s report, adoption of the 2024 annual report, covering of losses, elections for the Board of Directors and auditor, and several proposals from the Board. These proposals involve remuneration for the Board, adjustments to share capital, and authorizations for the Board to issue shares and warrants. No proposals from shareholders have been received. The meeting will require various voting majorities for different agenda items, with attendance and voting instructions provided. Shareholders can attend, vote by proxy, or submit postal votes by specified deadlines. The meeting will be conducted in English, and relevant documents are available on the company's website.

In 2024, DanCann Pharma A/S reported a revenue of DKK 7.37 million, a 21.4% increase from the previous year, with sales volumes rising by 18.5% to 17,027 units. The company's EBITDA deficit was reduced by 60.2% to DKK -5.13 million. DanCann secured approximately 26.3 MDKK in financing, resulting in a net financing of 6.7 MDKK and becoming debt-free by year-end. The cash position improved to DKK 3.47 million as of December 31, 2024. Strategically, the company focused on a lean, asset-light model, concentrating on cannabinoid-based medicines. There was growth in their Rx portfolio and progress in product development, including submissions to the Danish Medicines Agency. The Danish Pilot Programme for medicinal cannabis was confirmed as permanent. For 2025, DanCann anticipates revenue between DKK 10.0 to 12.5 million and an EBITDA of DKK -4.0 to -6.0 million. They plan to expand product offerings and pursue operational efficiencies to enhance shareholder value. DanCann Pharma A/S, founded in 2018, is a Danish biopharmaceutical company listed on the Spotlight Stock Market. The release includes forward-looking statements subject to risks and uncertainties, and the company advises caution in relying on these statements.

DanCann Pharma A/S har meddelat att deras årsredovisning för 2024 och årsstämman för 2025 har blivit uppskjutna. Årsredovisningen och kallelsen till årsstämman kommer nu att släppas den 4 april 2025, och årsstämman hålls den 24 april 2025. Företagets finansiella kalender har uppdaterats för att återspegla dessa ändringar. DanCann Pharma A/S är ett danskt läkemedelsföretag grundat 2018, specialiserat på cannabinoider och noterat på Spotlight Stock Market. För mer information kan man kontakta företagets VD, Jeppe Krog Rasmussen.

DanCann Pharma and Tetra Pharm Technologies have entered into a three-year agreement, with the possibility of extension, to integrate Tetra Pharm's ZYNDIKATE® drug delivery technology into DanCann's products. This technology is designed to improve the absorption and effectiveness of lipophilic molecules, such as cannabinoids, in the bloodstream. Both companies aim to expand this collaboration across the Nordic markets. The first product using this technology is expected to be available to Danish patients in the first half of 2026. DanCann Pharma focuses on cannabinoid-based medicines, while Tetra Pharm specializes in drugs for neurological and mental health disorders. The partnership seeks to enhance treatment quality and broaden the range of available therapies. The announcement includes forward-looking statements, which are subject to risks and uncertainties that could impact actual outcomes.

At an extraordinary general meeting on January 21, 2025, DanCann Pharma A/S decided to change the nominal value of its shares from DKK 0.001 to DKK 1 through a reverse share split at a 1,000:1 ratio. Consequently, 1,000 shares of DKK 0.001 each are consolidated into one share of DKK 1. A redemption notice was issued, giving shareholders four weeks, until February 19, 2025, to redeem shares. Shares below 1,000 or excess shares will be redeemed in cash at DKK 0.0023 per share. Payments are expected by February 26, 2025, and will be subject to withholding tax. Shareholders can contest the redemption price by May 26, 2025. The new nominal share value takes effect on February 25, 2025, with a new ISIN DK0063631999. The company's share capital will consist of 3,991,101 shares of DKK 1 and 234 shares of DKK 0.001 held by the company. Key dates include the last trading day of old shares on February 21, 2025, and the first trading day of new shares on February 24, 2025.